bioAffinity Technologies Inc. has announced that its patent related to a method for detecting lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent enhances the international protection of the company's diagnostic platform, CyPath® Lung, a noninvasive lung cancer diagnostic test. The Canadian patent, titled "System and Method for Determining Lung Health," safeguards the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum, and the application of flow cytometry to identify the presence of lung cancer cells. This development further validates the diagnostic platform of CyPath® Lung and expands its global intellectual property portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.